NO20040101L - Hemming av apoptoseprosessen og forbedring av cellenes yteevne - Google Patents

Hemming av apoptoseprosessen og forbedring av cellenes yteevne

Info

Publication number
NO20040101L
NO20040101L NO20040101A NO20040101A NO20040101L NO 20040101 L NO20040101 L NO 20040101L NO 20040101 A NO20040101 A NO 20040101A NO 20040101 A NO20040101 A NO 20040101A NO 20040101 L NO20040101 L NO 20040101L
Authority
NO
Norway
Prior art keywords
cell
enhancement
inhibition
cell performance
production
Prior art date
Application number
NO20040101A
Other languages
English (en)
Norwegian (no)
Inventor
Mitchell E Reff
Michael J Betenbaugh
Jr Bruno Figueroa
Eric Ailor
Marie Hardwick
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20040101L publication Critical patent/NO20040101L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20040101A 2001-07-10 2004-01-09 Hemming av apoptoseprosessen og forbedring av cellenes yteevne NO20040101L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30381301P 2001-07-10 2001-07-10
PCT/US2002/021606 WO2003006607A2 (fr) 2001-07-10 2002-07-10 Inhibition de l'apoptose et amelioration de la performance cellulaire

Publications (1)

Publication Number Publication Date
NO20040101L true NO20040101L (no) 2004-03-09

Family

ID=23173824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040101A NO20040101L (no) 2001-07-10 2004-01-09 Hemming av apoptoseprosessen og forbedring av cellenes yteevne

Country Status (13)

Country Link
US (1) US7604989B2 (fr)
EP (1) EP1414948B1 (fr)
JP (2) JP4435563B2 (fr)
KR (1) KR20040044433A (fr)
CN (1) CN1526011A (fr)
AT (1) ATE443131T1 (fr)
AU (1) AU2002315534B2 (fr)
CA (1) CA2452005C (fr)
DE (1) DE60233738D1 (fr)
MX (1) MXPA04000281A (fr)
NO (1) NO20040101L (fr)
WO (1) WO2003006607A2 (fr)
ZA (2) ZA200508985B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP1587934B1 (fr) 2003-02-01 2010-06-23 Millipore Corporation Elements genetiques ameliores permettant un niveau eleve d'expression
WO2005040364A1 (fr) * 2003-10-24 2005-05-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Nouvelles cellules animales recombinantes a production proteique elevee, procede de mise au point correspondant et procede de preparation de proteines de masse au moyen de ces cellules
EP1702071B1 (fr) * 2003-12-31 2012-02-22 Kalobios Inc. Systeme de transactivation de cellules mammaliennes
AU2005333513B2 (en) * 2004-07-23 2011-06-02 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
SG163592A1 (en) * 2004-07-23 2010-08-30 Immunomedics Inc Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
CA2649148C (fr) * 2006-04-13 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Gene transporteur de la taurine
US20100167396A1 (en) * 2006-04-21 2010-07-01 Bayer Healthcare Llc Application of Anti-Apoptotic Gene Expression in Mammalian Cells for Perfusion Culture
CN101802170A (zh) * 2007-01-08 2010-08-11 米利波尔公司 在存在降低水平的一或多种污染物的条件下制备重组蛋白的细胞培养方法
DK2300600T3 (en) 2008-06-13 2015-10-12 Janssen Biotech Inc Approaches for improving the viability and productivity in a cell culture
US20130065312A1 (en) * 2009-11-03 2013-03-14 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
KR102711314B1 (ko) 2018-06-28 2024-09-27 삼성디스플레이 주식회사 유기 발광 표시 장치

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2149326C (fr) 1992-11-13 2007-04-17 Mitchell E. Reff Sequences consensus kozak entierement alterees pour expression par des cellules de mammiferes
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5897992A (en) 1996-09-27 1999-04-27 Cold Spring Harbor Laboratory Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
ES2315016T3 (es) 1998-08-07 2009-03-16 Immunex Corporation Moleculas llamadas b7l-1.
CA2363621A1 (fr) 1999-02-26 2000-08-31 The Johns Hopkins University Inhibiteur de mort programmee de cellule
US6140118A (en) 1999-08-11 2000-10-31 Wisconsin Alumni Research Foundation Avian blastodermal cell lines
PT1650307E (pt) 1999-09-27 2010-10-21 Genentech Inc Métodos para preparação de proteínas recombinantes utilizando inibidores de apoptose
ES2257336T3 (es) * 1999-11-12 2006-08-01 MERCK & CO., INC. Derivados de diaril piperidil pirrol como agentes antiprotozoarios.
KR100454016B1 (ko) 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP1348758A1 (fr) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Cellules hôtes ayant des propriétés de survie améliorées et procédé pour produire ces cellules

Also Published As

Publication number Publication date
EP1414948B1 (fr) 2009-09-16
AU2002315534B2 (en) 2008-05-22
CA2452005A1 (fr) 2003-01-23
EP1414948A2 (fr) 2004-05-06
MXPA04000281A (es) 2004-07-23
JP2009118851A (ja) 2009-06-04
ATE443131T1 (de) 2009-10-15
JP4435563B2 (ja) 2010-03-17
WO2003006607A2 (fr) 2003-01-23
WO2003006607A9 (fr) 2003-04-10
WO2003006607A3 (fr) 2003-07-31
DE60233738D1 (de) 2009-10-29
JP2005525782A (ja) 2005-09-02
CN1526011A (zh) 2004-09-01
KR20040044433A (ko) 2004-05-28
ZA200508985B (en) 2006-07-26
CA2452005C (fr) 2011-03-15
EP1414948A4 (fr) 2006-06-21
US7604989B2 (en) 2009-10-20
US20030064510A1 (en) 2003-04-03
ZA200400137B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
NO20040101L (no) Hemming av apoptoseprosessen og forbedring av cellenes yteevne
Wang et al. Endoplasmic reticulum stress and the unfolded protein response in cerebral ischemia/reperfusion injury
Chiu et al. Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: a randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers
Mirmiran et al. Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: A review
Mao et al. Mitochondria: potential targets for osteoarthritis
MY138140A (en) N-aroylphenylalanine derivatives
BR9814817A (pt) Inibidores de apoptose de dipeptìdio e o uso dos mesmos
ZA200005475B (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with anglogenesis inhibitor.
AU548268B2 (en) 2-ammo-5-hydroxy-4-methylpyrimidinme derivatives
BR0009426A (pt) Compostos antiinflamatórios e imunossupressores inibidores de aderência celular
NO20013241D0 (no) Celleadhesjonsinhiberende anti-inflammatoriske og immunundertrykkende forbindelser
DK1438045T3 (da) Anvendelse af indol- og indolin-derivater ved behandling af obesitet eller til reduktion af födeindtag
NO20051967L (no) 3,4-disubstituerte pyroler og deres anvendelse ved behandling av inflammatoriske sykdommer.
DE60213407D1 (de) Zusammensetzungen zur hemmung der angiogenese
YU47100A (sh) Novi derivati dihidroksiheksanoinske kiseline
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
MX2007005348A (es) Formas amorfas y polimorficas de sodio de telmisartan.
Al-Malki Inhibition of α‐Glucosidase by Thiosulfinate as a Target for Glucose Modulation in Diabetic Rats
CA2037248A1 (fr) Methode de production de pates sechees
Singh et al. Modulation of immunocyte functions by a mucin-specific lectin from Aspergillus gorakhpurensis
WO2004012660A3 (fr) Proteines interactives avec mk2
WO2001042431A3 (fr) Regulation de la deformylase des mitochondries humaines
DK671188A (da) Acylderivater af 5-hydroxypyrimidin-forbindelser og farmaceutiske praeparater til behandling af pulmonaere, astmatiske, allergiske eller inflammatoriske tilstande
Nair Venous leg ulcer: Systemic therapy
Zouhir Efficacy of honey bee and Fagopyrum esculentum Moench ointment in the treatment of sub chronic wound in rabbits: A case control study

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application